全文获取类型
收费全文 | 232篇 |
免费 | 33篇 |
专业分类
基础医学 | 28篇 |
临床医学 | 12篇 |
内科学 | 108篇 |
皮肤病学 | 53篇 |
特种医学 | 2篇 |
外科学 | 5篇 |
综合类 | 1篇 |
预防医学 | 3篇 |
药学 | 3篇 |
肿瘤学 | 50篇 |
出版年
2021年 | 3篇 |
2020年 | 3篇 |
2019年 | 4篇 |
2018年 | 11篇 |
2017年 | 7篇 |
2016年 | 7篇 |
2015年 | 6篇 |
2014年 | 7篇 |
2013年 | 11篇 |
2012年 | 18篇 |
2011年 | 12篇 |
2010年 | 7篇 |
2009年 | 7篇 |
2008年 | 10篇 |
2007年 | 13篇 |
2006年 | 12篇 |
2005年 | 10篇 |
2004年 | 5篇 |
2003年 | 9篇 |
2002年 | 13篇 |
2001年 | 11篇 |
2000年 | 15篇 |
1999年 | 10篇 |
1998年 | 6篇 |
1997年 | 5篇 |
1996年 | 6篇 |
1994年 | 1篇 |
1993年 | 2篇 |
1992年 | 6篇 |
1991年 | 4篇 |
1990年 | 9篇 |
1989年 | 4篇 |
1988年 | 4篇 |
1987年 | 3篇 |
1986年 | 1篇 |
1985年 | 1篇 |
1984年 | 1篇 |
1983年 | 1篇 |
排序方式: 共有265条查询结果,搜索用时 15 毫秒
101.
Detection of Translocation t(11;14)(q13;q32) in Mantle Cell Lymphoma by Fluorescence in Situ Hybridization 总被引:8,自引:0,他引:8
下载免费PDF全文
![点击此处可从《The American journal of pathology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Jian-Yong Li Fanny Gaillard Anne Moreau Jean-Luc Harousseau Christian Laboisse Noël Milpied Rgis Bataille Herv Avet-Loiseau 《The American journal of pathology》1999,154(5):1449-1452
To assess an unequivocal diagnosis of mantle cell lymphoma (MCL), we have developed a fluorescence in situ hybridization (FISH) assay, enabling the demonstration of t(11;14)(q13;q32) directly on pathological samples. We have first selected CCND1 and IGH probes encompassing the breakpoint regions on both chromosomes. Then, we have defined experimental conditions enabling us to obtain bright clear-cut signals in all of the samples, independently of the initial fixation conditions. We have analyzed single-cell suspensions from 26 formalin-fixed, paraffin-embedded MCL samples with this set of probes. In all cases, we have found a fusion signal (ie, a t(11;14)(q13;q32) translocation) in 14% to 99% of cells (median, 87%). So far, IGH-CCND1 fusions have been detected in all of the 51 MCL patients that we have analyzed by FISH (either on paraffin-embedded tumor samples or on peripheral blood samples). Regarding the low sensitivity of other techniques used to diagnose t(11;14)(q13;q32) (ie, 70% to 75% for cytogenetics and 50% to 60% for polymerase chain reaction), our FISH assay is by far the most sensitive technique. Moreover, because of the quality of the fluorescent signals and the rapidity of the experiment, this technique is widely applicable, even in routine cytogenetics or pathology laboratories. As MCL patients are usually refractory to standard therapy, an unambiguous diagnosis is needed to propose adapted therapeutic strategies, and this highly sensitive assay may be of great value for accurate diagnosis in difficult cases. 相似文献
102.
Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B‐cell lymphoma
下载免费PDF全文
![点击此处可从《American journal of hematology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Fabrice Jardin Anais Pujals Laura Pelletier Elodie Bohers Vincent Camus Sylvain Mareschal Sydney Dubois Brigitte Sola Marlène Ochmann François Lemonnier Pierre‐Julien Viailly Philippe Bertrand Catherine Maingonnat Alexandra Traverse‐Glehen Philippe Gaulard Diane Damotte Richard Delarue Corinne Haioun Christian Argueta Yosef Landesman Gilles Salles Jean‐Philippe Jais Martin Figeac Christiane Copie‐Bergman Thierry Jo Molina Jean Michel Picquenot Marie Cornic Thierry Fest Noel Milpied Emilie Lemasle Aspasia Stamatoullas Peter Moeller Martin J.S Dyer Christer Sundstrom Christian Bastard Hervé Tilly Karen Leroy 《American journal of hematology》2016,91(9):923-930
Primary mediastinal B‐cell lymphoma (PMBL) is an entity of B‐cell lymphoma distinct from the other molecular subtypes of diffuse large B‐cell lymphoma (DLBCL). We investigated the prevalence, specificity, and clinical relevance of mutations of XPO1, which encodes a member of the karyopherin‐β nuclear transporters, in a large cohort of PMBL. PMBL cases defined histologically or by gene expression profiling (GEP) were sequenced and the XPO1 mutational status was correlated to genetic and clinical characteristics. The XPO1 mutational status was also assessed in DLBCL, Hodgkin lymphoma (HL) and mediastinal gray‐zone lymphoma (MGZL).The biological impact of the mutation on Selective Inhibitor of Nuclear Export (SINE) compounds (KPT‐185/330) sensitivity was investigated in vitro. XPO1 mutations were present in 28/117 (24%) PMBL cases and in 5/19 (26%) HL cases but absent/rare in MGZL (0/20) or DLBCL (3/197). A higher prevalence (50%) of the recurrent codon 571 variant (p.E571K) was observed in GEP‐defined PMBL and was associated with shorter PFS. Age, International Prognostic Index and bulky mass were similar in XPO1 mutant and wild‐type cases. KPT‐185 induced a dose‐dependent decrease in cell proliferation and increased cell‐death in PMBL cell lines harboring wild type or XPO1 E571K mutant alleles. Experiments in transfected U2OS cells further confirmed that the XPO1 E571K mutation does not have a drastic impact on KPT‐330 binding. To conclude the XPO1 E571K mutation represents a genetic hallmark of the PMBL subtype and serves as a new relevant PMBL biomarker. SINE compounds appear active for both mutated and wild‐type protein. Am. J. Hematol. 91:923–930, 2016. © 2016 Wiley Periodicals, Inc. 相似文献
103.
Patrick J. Hayden Simona Iacobelli José Antonio Pérez-Simón Anja van Biezen Monique Minnema Riitta Niittyvuopio Stefan Schönland Ellen Meijer Didier Blaise Noel Milpied Francisco J. Márquez-Malaver Joan Hendrik Veelken Johan Maertens Mauricette Michallet Jörg Cammenga Stephanie N'Guyen Dietger Niederwieser Mathilde Hunault-Berger Jean Henri Bourhis Jakob Passweg Arancha Bermudez Yves Chalandon Ibrahim Yakoub-Agha Laurent Garderet Nicolaus Kröger 《European journal of haematology》2020,104(3):181-189
104.
Moreau P Harousseau JL Wijdenes J Morineau N Milpied N Bataille R 《British journal of haematology》2000,109(3):661-664
To improve the complete response (CR) rate in advanced multiple myeloma (MM) without increasing the toxicity of high-dose therapy, we have used a new conditioning regimen. A combination of BE-8 [an anti-interleukin 6 (IL-6) murine monoclonal antibody] and dexamethasone followed by high-dose melphalan (220 mg/m2) and autologous stem cell transplantation was used to treat a series of 16 patients with advanced multiple myeloma. A strong inhibition of IL-6 activity evaluated by quantification of C-reactive protein was observed in all patients and was correlated with the high CR rate achieved with this combination therapy. 相似文献
105.
Bay JO Dhédin N Goerner M Vannier JP Marie-Cardine A Stamatoullas A Jouet JP Yakoub-Agha I Tabrizi R Faucher C Diez-Martin JL Nunez G Parody R Milpied N Espérou H Garban F Galambrun C Kwiatkovski F Darlavoix I Zinaï A Fischer A Michallet M Vernant JP 《Transplantation》2005,80(6):782-788
BACKGROUND: The use of monoclonal antibodies against interleukin-2 receptor (IL-2R)-alpha chains could be an effective treatment of acute graft-versus-host disease (GvHD). Experimental model and clinical studies have reported various results. METHODS: Inolimomab is a murine anti-IL-2R. Eighty-five patients were evaluated retrospectively for the safety and efficacy of inolimomab given for the treatment of steroid-resistant acute GvHD (aGvHD) following allogeneic hematopoietic stem cell transplantation (HSCT). Diseases were immune deficiency, hematological malignancies, or solid tumors. Seventy-six percent of the patients received a myeloablative regimen. The source of HSCT was bone marrow for 45 patients, peripheral blood for 36 patients, and cord blood for 4 patients. Donors were 49 siblings and 36 unrelated. Acute GvHD was diagnosed within a median of 28 days after transplantation (grade II, 26 patients; grade III, 26 patients; grade IV, 33 patients). Inolimomab was administered in the event of steroid-resistant aGvHD with a median dose of 0.468 mg per kg (median period of treatment: 18 days). RESULTS: Twenty-five complete responses and 29 partial responses (total response rate: 63%) were observed with no side effects. There was no correlation between aGvHD grading and quality of response. Better responses were observed in cutaneous aGvHD. The overall survival probability was 26% (median follow-up: 20 months). Fifty-seven percent of patients died of toxicity related mortality, mostly aGvHD. Response to inolimomab seemed sustained (11% relapse in responders). CONCLUSION: Inolimomab is well-tolerated and effective for severe steroid-resistant aGvHD. The optimum regimen remains to be defined. 相似文献
106.
Pfreundschuh M Trümper L Osterborg A Pettengell R Trneny M Imrie K Ma D Gill D Walewski J Zinzani PL Stahel R Kvaloy S Shpilberg O Jaeger U Hansen M Lehtinen T López-Guillermo A Corrado C Scheliga A Milpied N Mendila M Rashford M Kuhnt E Loeffler M;MabThera International Trial Group 《The lancet oncology》2006,7(5):379-391
BACKGROUND: The role of rituximab in combination with different CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-like chemotherapy regimens in young patients with good-prognosis diffuse large-B-cell lymphoma remains to be defined. We aimed to compare CHOP-like chemotherapy and rituximab with CHOP-like chemotherapy alone in these patients. METHODS: 824 patients who were from 18 countries; aged 18-60 years; and who had no risk factors or one risk factor according to age-adjusted International Prognostic Index (IPI), stage II-IV disease, or stage I disease with bulk were enrolled. These patients were randomly assigned to six cycles of CHOP-like chemotherapy and rituximab (n=413) or to six cycles of CHOP-like chemotherapy alone (n=411). Bulky and extranodal sites received additional radiotherapy. The primary endpoint was event-free survival; secondary endpoints were response, progression under therapy, progression-free survival, overall survival, and frequency of toxic effects. Analyses were done by intention to treat and per protocol. This trial is registered at http://www.clinicaltrials.gov, NCT 00064116. FINDINGS: After a median follow-up of 34 months (range 0.03-61), patients assigned chemotherapy and rituximab had increased 3-year event-free survival compared with those assigned chemotherapy alone (79% [95% CI 75-83] vs 59% [54-64]; difference between groups 20% [13-27], log-rank p<0.0001), and had increased 3-year overall survival (93% [90-95] vs 84% [80-88]; difference between groups 9% [3-13], log-rank p=0.0001). Event-free survival was affected by treatment group, presence of bulky disease, and age-adjusted IPI: after chemotherapy and rituximab, a favourable subgroup (ie, IPI=0, no bulk) could be defined from a less-favourable subgroup (ie, IPI=1 or bulk, or both). Groups did not differ in the frequency of adverse events. INTERPRETATION: Rituximab added to six cycles of CHOP is an effective treatment for young patients with good-prognosis diffuse large-B-cell lymphoma. The definition of two prognostic subgroups allows for a more refined therapeutic approach for these patients. 相似文献
107.
M Michallet K Bilger F Garban M Attal A Huyn D Blaise N Milpied P Moreau P Bordigoni M Kuentz A Sadoun J Y Cahn G Socié X Thomas P Arnaud N Raus V Lhéritier A Pigneux J M Boiron 《Journal of clinical oncology》2001,19(14):3340-3349
PURPOSE: To analyze the impact of pre- and posttransplantation factors on the outcome of allogeneic transplantation after nonmyeloablative conditioning regimens. PATIENTS AND METHODS: Ninety-two allogeneic transplantations after nonmyeloablative preparative regimens were reported to the Société Fran?aise de Greffe de Moelle Registry registry. Initial diagnoses were lymphoid diseases (n = 22), myeloma (n = 14), acute leukemia and myelodysplasia (n = 41), chronic myelogenous leukemia (n = 12), and solid tumors (n = 3). Forty-six patients had previously received a transplant, and 49 had progressive disease before transplantation. Three types of conditioning regimens were used with fludarabine or antithymocyte globulins. Eighty-nine patients underwent transplantation, 60 from peripheral-blood progenitor cells. Eighty-six patients received graft-versus-host disease (GHVD) prophylaxis for a median duration of 53 days. RESULTS: Seventy-nine patients engrafted, with 40 complete and 21 mixed chimerisms. The acute GHVD rate at 3 months was 50% +/- 11%. Fifty-two patients achieved complete remission and 12, partial remission. At 18 months after transplantation, the overall survival (OS) and the transplant-related mortality (TRM) were 32% +/- 12% and 38% +/- 14%, respectively. Initial diagnosis and disease status before transplantation significantly influenced survival. Age and GHVD prophylaxis type significantly influenced TRM. We also showed an impact of GHVD prophylaxis duration on OS and TRM. In multivariate analysis, three factors remained of prognostic value on OS: initial diagnosis, disease status at transplantation, and GHVD prophylaxis duration. CONCLUSION: This series shows encouraging results from nonmyeloablative conditioning regimens before allotransplantation and demonstrates the impact of some pre- and posttransplantation factors on outcome after transplantation. 相似文献
108.
Monnereau A Orsi L Troussard X Berthou C Fenaux P Soubeyran P Marit G Huguet F Milpied N Leporrier M Hemon D Clavel J 《Cancer causes & control : CCC》2008,19(10):1147-1160
Objective To study potential role of smoking and alcohol in lymphoid neoplasms (LN).
Methods A case–control study that included 824 cases and 752 hospital controls aged 18–75 years was conducted. Cases were newly diagnosed
with non-Hodgkin’s or Hodgkin’s lymphoma, multiple myeloma, or lymphoproliferative syndrome (LPS). Controls were matched with
the cases by gender, age, and center.
Results Overall, smoking was not related to LN. However, average tobacco consumption tended to be inversely related to non-Hodgkin’s
lymphoma (NHL), LPS, and the hairy cell leukemia (HCL) subtype, with a significant negative trend for the latter (OR of 0.4,
0.2, 0.1 for consumptions of ≤10, 11–20, >20 cig/day). An inverse association between ‘ever drinking’ and Hodgkin’s lymphoma
(HL: OR = 0.5 [0.3–0.8]) and NHL (OR = 0.7 [0.5–1.0]) was evidenced and restricted to the diffuse large B-cell lymphoma subtype,
with significant negative trends. The controls’ smoking and drinking habits were similar to those of French population. The
results remained unchanged after adjustment for potential confounding factors and when smoking and drinking were both included
in the models.
Conclusion Results are consistent with those of several previous studies and suggest a direct or indirect protective effect of smoking
with respect to HCL although based on small numbers. The negative relationship between alcohol consumption and Hodgkin’s and
NHL, also previously reported, needs further investigations. 相似文献
109.
110.